⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Denosumab (RANKL Inhibition)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-01 — Podocyte mPGES-2 Determines Renal Aging and Contributes to Senile Osteoporosis.: cross-connection with mpges2-inhibitors: Both address senile osteoporosis but via distinct entry points: denosumab blocks RANKL-driven osteoclast activity, while mPGES-2 inhibition proposes a kidney-origin (podocyte senescence) upstream driver of age-related bone loss. (novelty: 3)
Open questions
Related
Contributing findings
Advances in the study of the role of bone immunity in physiological and pathological processes related to bone metabolism.
03-aug-2026
novelty 2
per-area 2
strengthens